US Patent 8007798 Treatment of complement-associated disorders
Patent 8007798 was granted and assigned to Genentech on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 2 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+318 characters)
Article
Patent abstract
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08007798 Treatment of complement-associated disorders US Patent 8007798 Treatment of complement-associated disorders
Infobox
Patent Number
0800779800
Patent Number
800779800
Edits on 28 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080077980
Date of Patent
August 30, 2011
0Patent Application Number
112498250
Date Filed
October 12, 2005
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080077980
Date of Patent
August 30, 2011
0Patent Application Number
112498250
Date Filed
October 12, 2005
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08007798 Treatment of complement-associated disorders
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08007798
Date of patent
August 30, 2011
Patent application number
11249825
Date Filed
October 12, 2005
Patent primary examiner
Find more entities like US Patent 8007798 Treatment of complement-associated disorders
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
